Intellia Therapeutics
Intellia Therapeutics raises $350M Follow-on Offering at $4.5B valuation
Quick Facts
Intellia Therapeutics: Follow-on Offering Funding Round
Intellia Therapeutics has successfully raised $350M in Follow-on Offering funding, reaching a valuation of $4.5B.
Company Overview
In vivo CRISPR gene editing
Funding Details
The Follow-on Offering round was led by Atlas Venture, with participation from Novartis Venture Fund, Venrock, Lilly Asia Ventures.
Company Information
- Headquarters: 40 Erie Street, Cambridge, MA 02139
- Founded: 2014
- Employees: 400+
- Category: Biotech
Investment
Intellia Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Atlas Venture: Verified investor in Follow-on Offering
- Novartis Venture Fund: Verified investor in Follow-on Offering
- Venrock: Verified investor in Follow-on Offering
- Lilly Asia Ventures: Verified investor in Follow-on Offering
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...